Patents by Inventor Peter Bringmann

Peter Bringmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230226232
    Abstract: Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 20, 2023
    Inventors: Daniel CHURCH, Peter BRINGMANN, Grace CASTRO, Thea LU, Shelby REINHARDT, Felicia SANTA MARIA, Adonis STASSINOPOULOS
  • Patent number: 11554185
    Abstract: Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: January 17, 2023
    Assignee: Cerus Corporation
    Inventors: Daniel Church, Peter Bringmann, Grace Castro, Thea Lu, Shelby Reinhardt, Felicia Santa Maria, Adonis Stassinopoulos
  • Publication number: 20220089685
    Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: June 18, 2021
    Publication date: March 24, 2022
    Inventors: Alan Brooks, Richard Feldman, Jian-Ming GU, Shaun Lippow, Shujun Yuan, Peter Bringmann
  • Patent number: 11104718
    Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bayer HealthCare LLC
    Inventors: Alan Brooks, Richard Feldman, Jian-Ming Gu, Shaun Lippow, Shujun Yuan, Peter Bringmann
  • Publication number: 20190359687
    Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: November 14, 2017
    Publication date: November 28, 2019
    Inventors: Alan Brooks, Richard Feldman, Jian-Ming GU, Shaun Lippow, Shujun Yuan, Peter Bringmann
  • Publication number: 20190209718
    Abstract: Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.
    Type: Application
    Filed: December 28, 2018
    Publication date: July 11, 2019
    Inventors: Daniel CHURCH, Peter BRINGMANN, Grace CASTRO, Thea LU, Shelby REINHARDT, Felicia SANTA MARIA, Adonis STASSINOPOULOS
  • Publication number: 20190085289
    Abstract: Provided are methods, kits, and compositions for preparing platelet compositions suitable for infusion, including improved methods, compositions, and kits for pathogen inactivation of an apheresis-derived preparation of platelets.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 21, 2019
    Inventors: William GREENMAN, Adonis STASSINOPOULOS, Elan WEINER, Peter BRINGMANN, Felicia SANTA MARIA
  • Publication number: 20080057076
    Abstract: Novel nucleic acids, polypeptide sequences, and nucleic acid regulators thereof, have been identified which code for a fibroblast growth factor (FGF), preferably FGF-20 or FGF-23, a class of polypeptides involved in development, differentiation, and morphogenesis, e.g., in cell-cell signalling and cell proliferation. An FGF of the present invention, fragments thereof, and derivatives thereof, have one or more of the following biological activities, e.g., promoting wound healing; promoting neuronal survival; stimulating cell proliferation, e.g., proliferation of stem cells, fibroblasts, neurons, glia, oligodendrocytes, Schwann cells, or progenitors thereof; modulating differentiation of cells; inducing embryonic development; stimulating neurite outgrowth; enhancing recovery from nerve or neuronal damage; stimulating myelination; stimulating angiogenesis; receptor binding activity; modulating tumorigenesis, etc.
    Type: Application
    Filed: June 22, 2007
    Publication date: March 6, 2008
    Applicant: Schering Aktiengesellschaft
    Inventors: Peter Bringmann, Daryl Faulds, Branislava Mitrovic, Subha Srinivasan